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Abstract: The 1,4-benzoquinone moiety is a common structural feature in a large number 
of compounds that have received considerable attention owing to their broad spectrum of 
biological  activities.  The  cytotoxic  and  antiproliferative  properties  of  many  natural 
sesquiterpene quinones and hydroquinones from sponges of the order Dictyoceratida, such 
as  avarol,  avarone,  illimaquinone,  nakijiquinone  and  bolinaquinone,  offer  promising 
opportunities  for  the  development  of  new  antitumor  agents.  The  present  review 
summarizes the structure and cytotoxicity of natural terpenequinones/hydroquinones and 
their bioactive analogues and derivatives. 
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1. Introduction  
The few therapeutic novelties of synthetic origin that have appeared on the pharmaceutical market, 
of which more than 88% are based on preexisting structures, have flooded the pharmaceutical world 
with very similar products. This has led to a new and enthusiastic retrospective appraisal of the active 
principles of the molecules integrating medicinal plants and different natural sources. It is for these 
reasons  that  research  on  natural  compounds  has  aroused  considerable  interest  at  the  academic, 
commercial and governmental levels. 
Of the different natural sources, the sea has become an important basis for the collection of natural 
compounds of use to humans and it is clear that this will continue to be the case in the future [1–13]. 
Interest in marine organisms, both animals and plants, as sources of active substances was boosted at 
the beginning of the seventies by the work of several marine research teams: Universities of Hawaii 
and Oklahoma and The Scripps Institution of Oceanography in California, as well as other teams in 
Japan  and  Europe.  This  began  with  the  isolation  of  prostaglandins  from  corals,  followed  by  the 
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discovery  of  other  derivatives.  In  recent  years,  it  has  been  possible  to  isolate  and  characterize 
thousands of compounds, many of which exert important activities in several biological systems [14]. 
The discovery of drugs from marine natural products has enjoyed a renaissance in the past few 
years [15–19]. Ziconotide (Prialt
®; Elan Pharmaceuticals), a peptide originally discovered in a tropical 
cone snail, was the first marine-derived compound to be approved in the United States in December 
2004 for  the  treatment  of pain  [20].  Then,  in  October 2007,  trabectedin (Yondelis
®;  PharmaMar) 
became  the  first  marine  anticancer  drug  to  be  approved  in  the  European  Union  [21].  In  a  recent 
congress held by the American Society of Oncology (Chicago, June 2010), attention was drawn to the 
antitumor properties of eribulin mesylate (E7389), designed by the Japanese laboratory Eisai (Eisai 
Research Institute, Andover, MA, USA) for the treatment of breast cancer. This is a synthetic analogue 
of  the  natural  product  halichondrin  B,  isolated  from  Halichondria  okadai  (Lissodendoryx  sp.),  a 
marine  sponge  commonly  found  in  Japanese  seas;  its  antitumor  activity  was  discovered  in  1986. 
Eribulin  binds  to  the  vinca  domain  of  tubulin  and  inhibits  the  polymerization  of  tubulin  and  the 
assembly of microtubules, resulting in the inhibition of mitotic spindle assembly, the induction of cell 
cycle arrest at G2/M, and, potentially, tumor regression. Eribulin mesylate is now in phase II clinical 
trials and is active in metastatic or locally advanced breast cancer [22,23]. 
In particular, the cytotoxic and antiproliferative properties of many natural sesquiterpene quinones 
and  hydroquinones  from  sponges  of  the  order  Dictyoceratida  [24]  such  as  avarol,  avarone, 
illimaquinone, nakijiquinone and bolinaquinone offer promising opportunities for the development of 
new antitumor agents [25,26]. This has sparked interest in the chemical composition and cytotoxicity 
of a large number of marine species that contain metabolites with hybrid structures between terpenes 
and  quinones/hydroquinones.  Related  to such terpenequinone  structures, several studies have  been 
published addressing the chemistry, activity and mechanisms of action of the compounds [27–33]. 
The present review addresses the terpenylquinones of marine origin with cytotoxic properties that 
are active against different tumor cell lines. It also deals with the cytotoxic hydroquinones and some 
semisynthetic analogues of bioactive terpenequinones. The compounds described herein are mainly 
natural  sesquiterpenes  and  share  a  decalin  structure,  bound  via  a  1C  carbon  chain  to  a  ring  of 
differently functionalized p-benzoquinone or hydroquinone. Cytotoxic terpenequinone/hydroquinones 
are usually metabolites that incorporate a bicyclic sesquiterpene unit coupled to a quinone or quinol. 
Most of these possess a drimane or rearranged drimane skeleton. In the present work they have been 
grouped on the basis of the structural resemblance of the bicyclic moiety with some diterpene skeletons.  
2. Terpenylquinones with a Clerodane-Type Decalin Ring  
From extracts of sponges from the family Spongiidae, collected in Okinawa, it has been possible to 
isolate several compounds with an amino acid moiety on the benzoquinone ring: nakijiquinones A (1), 
B (2), C (3) and D (4) [34–36], or with a benzoxazol moiety: nakijinol (5) (Figure 1). It should be 
noted that the presence of aminoquinone compounds is not very common in natural products, these 
substances being the first examples of sesquiterpenequinones of natural origin with an amino acid or 
heterocyclic moiety. Nakijiquinones A (1), B (2), C (3) and D (4) showed in vitro cytotoxicity against 
L-1210 (IC50 values between 2.8 and 8.1 µg/mL) and KB (IC50 values between 1.2 and 7.6 µg/mL).  Mar. Drugs 2010, 8  
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Figure 1. Nakijiquinones. 
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The new dimeric sesquiterpenoid quinones nakijiquinones E (6) and F (7) were isolated from an 
Okinawan marine sponge [37]. These nakijiquinones were the first dimeric sesquiterpenoid quinones 
possessing a 3-aminobenzoate moiety. Nakijiquinones G–I (8–10), containing a different amino group Mar. Drugs 2010, 8  
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derived from amino acids, were isolated from Okinawan marine sponges of the family Spongiidae, and 
showed modest cytotoxicity and inhibitory activity against HER2 kinase, while nakijiquinone H (9) 
exhibited antimicrobial activity [38]. 
Nakijiquinones J–R (17, 11, 12, 18, 13, 14, 19 and 16), at 1 mM were tested for inhibitory activities 
against EGFR and HER2 tyrosine kinases. Among them, nakijiquinones P (19) and R (16) exhibited 
inhibitory  activities  against  EGFR  (76  and  >99%  inhibition,  respectively),  while  nakijiquinones 
N (13), O (14) and R (16) showed inhibitory activities against HER2 (66%, 59% and 52% inhibition, 
respectively) [39]. The HER2/Neu tyrosine kinase receptor is hugely overexpressed in about 30% of 
primary breast, ovary, and gastric carcinomas. Nakijiquinones are the only naturally occurring inhibitors 
of  this  important  oncogene,  and  structural  analogues  of  nakijiquinones  may  display  inhibitory 
properties against other tyrosine kinase receptors involved in cell signaling and proliferation [40]. 
Another type of compound with bioactive properties includes those whose benzo(hydro)quinone 
ring  is  substituted  by  a  methoxycarbonyl  group,  as  is  the  case  of  polyfibrospongols  and 
smenospondiol. Extracts of the marine sponge Polyfibrospongia australis, collected in Taiwan, were 
used to isolate polyfibrospongols A (20) and B (21) (Figure 2) [41], compounds showing cytotoxic 
activity  against  different  tumor  lines.  From  the  South  China  sponge  Dysidea  arenaria,  a  new 
sesquiterpenoid  hydroquinone,  19-hydroxy-polyfibrospongol  B  (22),  was  isolated,  along  with 
polyfibrospongol B (21) and other known terpenequinones [42]. 
Also  showing  cytotoxic,  as  well  as  antibacterial,  activity  is  smenospondiol  (23),  isolated  from 
dichloromethane  extracts  of  several  species  of  the  genus  Smenospongia  and  with  a  very  similar 
structure [43,44]. This compound has also been called dictyoceratin A by other authors [45]. These 
compounds  showed  interesting  levels  of  cytotoxicity  when  assayed  against  the  P-388  (mouse 
lymphoma),  KB-16  (human nasopharyngeal  carcinoma) and A-549 (human lung carcinoma) cells, 
their CI50 values lying between 0.6 and 2.0 µg/mL. 
5-epi-Ilimaquinone (24) showed cytotoxic activity (IC50) against P-388 leukemia cells (2.2 µg/mL) 
and different solid tumors: A-549 (0.9 µg/mL), HT-29 (3.4 µg/mL) and B16/F10 (1.1 µg/mL) [46]. It 
has been suggested that ilimaquinone (25) induces a concentration-dependent antiproliferative effect in 
several types of cancer cell lines, including PC-3 and LNCaP prostate cancer, A549 non-small cell 
lung cancer and Hep3B hepatocellular carcinoma cells. The anticancer mechanism of ilimaquinone in 
the representative PC-3 cells was identified. Ilimaquinone (25) induced a time-dependent increase in 
G1 phase arrest and a subsequent increase in the hypodiploid sub-G1 phase (apoptosis) of the cell 
cycle. The cell cycle arrest was associated with a sustained high level of nuclear cyclin E but the 
absence of DNA synthesis, according to flow cytometric analysis, indicated an incomplete S phase. 
Although ilimaquinone-induced Golgi vesiculation, the data showed that the inhibition of cancer cell 
growth  did  not  occur  through  Golgi  fragmentation.  Ilimaquinone  did  not  activate  extracellular 
signal-regulated  kinase  and  phosphatidylinositol  3-kinase  but  induced  an  up-regulation,  nuclear 
translocation  and  gene  153-induced  DNA  damage  (CHOP/GADD153).  Furthermore,  the 
ilimaquinone-mediated  antiproliferative  effect  was  significantly  reduced  in  antisense 
CHOP/GADD153-overexpressing cells. Ilimaquinone (25) also inhibited the DNA binding of NF-κB; 
however, this inhibitory effect cannot explain the ilimaquinone-induced anticancer effect. In brief, it is 
suggested that ilimaquinone (25) induces its antiproliferative effect through the G1 arrest of the cell 
cycle  and  the  up-regulation  and  nuclear  translocation  of  CHOP/GADD153  [32].  Bioassay-guided Mar. Drugs 2010, 8  
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isolation from the marine sponge Hippospongia sp., collected at Palau, led to the isolation of three 
sesquiterpene  quinone  metabolites:  ilimaquinone  (25),  5-epi-ilimaquinone  (24),  and  
5-epi-isospongiaquinone (34)  (Figure 2).  The  cytotoxicity against  the  NCI-H460, HepG2, SF-268, 
MCF-7, HeLa, and HL-60 human tumor cell lines, the inhibitory effects on the maturation of starfish 
oocytes, and cell cycle arrest in the HepG2 cell line were evaluated [47]. 
Figure 2. Polyfibrospongols, ilimaquinones, smenospongines and related compounds. 
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One compound closely linked to those above is glycinylilimaquinone (26), a metabolite isolated 
from  a  specimen  from  the  genus  Fasciosponia  from  the  Phillipines,  its  structure  having  being 
determined  by  spectroscopic  analysis  and  chemical  synthesis  [48,49].  This  structure  displayed 
cytotoxic  activity,  with  IC50  =  7.8  µg/mL,  against  a  human  carcinoma  tumor  cell  line  (HT-29). 
However, when it was tested against P-388 mouse lymphoma in vivo, the maximum dose tolerated did 
not display cytotoxic activity. 
Other compounds with free hydroxyl and/or amino functions on the benzo(hydro)quinone ring have 
been isolated from the genus Smenospongia. Bioassays performed on the dichloromethane extract of 
different species of this genus revealed both cytotoxic and antibacterial activities. From this extract, 
smenosquinone  (27),  smenospongidine  (28),  smenospongiarine  (30),  smenospongorine  (32)  and 
smenorthoquinone (35) were isolated [50]. The cytotoxicity of some of these compounds was assessed 
against L.1210 leukemia cells. The results for smenoquinone, smenospongiarin and smenortoquinone 
were IC50: 2.5, 4.0 and 1.5 µg/mL, respectively. 
The  methanol-chloroform  extract  of  several  species  of  the  genus  Smenospongia  also  afforded 
smenospongin (36), from the enantiomeric series with respect to the above described compounds. 
Smenospongin (36), which has also been isolated from Dactylospongia elegans, showed promising 
biological  activities:  cytotoxicity  against  L-1210  leukemia  cells  with  a  LD50  of  1  µg/mL. 
Smenospongine  (36)  induced  erythroid  differentiation  and  G1  phase  arrest  of  K562  chronic 
myelogenous leukemia cells. In that study, the effect of smenospongine (36) on the cell cycles of other 
leukemia  cells,  including  HL60  human  acute  promyelocytic  leukemia  cells  and  U937  human 
histiocytic  lymphoma  cells,  was  investigated  by  flow  cytometric  analysis.  Smenospongine  (36) 
induced dose-dependent apoptosis in HL60 and U937 cells. Smenospongine (36) treatment increased 
the expression of p21 and inhibited the phosphorylation of Rb in K562 cells, suggesting the p21-Rb 
pathway plays an important role in G1 arrest in K562 cells. However, based on a luciferase assay using 
transfected  K562  cells,  the  p21  promoter  was  not  activated  by  smenospongine  (36)  treatment. 
Smenospongine might induce p21 expression via a mechanism other than the transactivation of the p21 
promoter [51]. 
D. elegans, from Papua Nueva Guinea and Thailand, contains a total of 17 merosesquiterpenoids, 
among  which  are  (+)-epi-smenospongiarin  (31)  and  (+)-epi-smenospongidin  (29)  [46].  These 
compounds  were  assayed  in  vitro  against  solid  tumor  models  (A-549,  HT-29  and  B16/F10)  and 
leukemia cells (P-388), (+)-epi-smenospongiarin (31), with IC50 values between 0.6 and 0.9 µg/mL 
being of particular interest. 
A  new  sesquiterpene  aminoquinone,  5-epi-smenospongorine  (33),  together  with  nine  known 
sesquiterpene quinone/phenols, were isolated from the marine sponge Dactylospongia elegans. The 
structure-activity  relationship  study  of  these  compounds  revealed  that  the  quinone  skeleton  is 
indispensable and the amino group plays an important role for their differentiation-inducing activity to 
K562 cells into erythroblast [52]. The new sesquiterpenoid aminoquinone, cyclosmenospongine (37), 
containing a dihydropyran ring, was isolated from an Australian marine sponge Spongia sp., along 
with the known metabolites, smenospongiarine (30), ilimaquinone (25) and smenospongine (36) [53]. 
A unified synthesis of several quinone sesquiterpenes is described by Ling et al. [54]. 
Avarol (38), a sesquiterpene hydroquinone, and its quinone derivative avarone (49) (Figure 3) are 
secondary metabolites isolated from the marine sponge Dysidea avara. Both compounds were first Mar. Drugs 2010, 8  
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discovered as anti-leukemia agents in vitro and in vivo, and later it was found that they had an in vitro 
inhibitory capacity against HIV-1 [55–60]. Controlled clinical studies revealed, however, that it was 
not efficient in the clinical treatment of patients with AIDS. Additionally, the potent T-lymphotropic 
cytostatic activity shown by avarol (38), and its low toxicity in mice, its ability to cross the blood-brain 
barrier and its ability to stimulate the synthesis of interferon make both these compounds optimum 
candidates for transformations aimed at improving their cytostatic and antiviral activity [12–17,55–60].  
Figure 3. Avarols and avarones. 
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The first avarone analogues were obtained by semisynthesis. Among the main substitutions are 
those performed on the quinone ring, including hydroxyl, methylamino, ethylamino, and glucosamine 
groups and different essential amino acids at positions 3’ or 4’ [56,61]. Cytostatic activity was assayed 
by  analyzing  the  capacity  of  these  compounds  to  inhibit  the  growth  of  fibroblasts,  lymphocytic 
leukemia  and  lymphoblastic  B  and  T  cells.  Avarol  (38)  and  avarone  (49)  showed  very  similar 
inhibitory activity against the cell lines assayed (IC50 = 13.9–15.6 µM), as did the methyl, ethyl and 
glucosylaminated analogues and the alaninyl, phenylalaninyl and leucinyl derivatives. By contrast, the 
serinyl and cysteinyl derivatives were significantly less active. Antiviral activity was evaluated against 
the  following  viral types:  HIV-1, ASFV, HSV-1, HSV-2, polio  and VSV. Because of its activity 
(IC50 = 0.04 µM HSV-1 and 0.2 µM HSV-2), acyclovir is used like control compound against herpes 
simplex. Avarone (49) showed a more potent activity against HIV-1 (IC50 = 1.5 µM) than avarol (38) 
(IC50 = 2.9 µM) in vitro. Among the derivatives of avarone, modification in the quinone ring always 
afforded a loss of anti-HIV-1 potential, with the exception of leucinyl- and cysteicyl-avarone, which 
were as potent as avarone (49), the latter derivative being even more selective. 
All the derivatives selectively inhibited polio virus, but were almost completely inactive against the 
other viruses assayed. Against polio virus, avarol (38), avarone (49) and the 3’-methyl and 3’-ethyl 
aminoderivatives were more potent and selective inhibitors. The 3’-substituted analogues maintained 
potency and selectivity, while the 4’-substituted analogues showed a significantly lower potency and in 
some cases selectivity, the only exceptions being the 4’serinyl and 4’-cysteinyl derivatives of avarone. 
Different derivatives of avarol and avarone have been isolated from other species of the genus 
Dysidea.  These  included,  neoavarol  (39),  neoavarone  (50),  4’-methoxyavarone  (51)  and 
4’-methoxyneoavarone  (52) isolated from a specimen in  Okinawa  [62],  while from the  extract of 
Dysidae  cinera  (collected  in  the  Red  Sea),  6’-hydroxyavarol  (40),  6’-acetoxyavarol  (41), 
3’-hydroxyavarone  (53),  6’-acetoxyavarone  (55),  3’,6’-dihydroxyavarone  (56)  and  
6’-hydroxy-4’-methoxyavarone (57) were isolated [63]. Some of these compounds showed cytotoxic, 
antimicrobial  and  anti-HIV  properties.  The  results  of  cytotoxicity  assays  against  P-388  mouse 
lymphoma  indicated  high  potency  for  3’-hydroxyavarone  (53),  6’-acetoxyavarol  (41)  and 
3,6’-dihydroxyavarone (56), with IC50 values of 0.6, <0.6 and 1.2 µg/mL, respectively. 
Additionally, and related to the above, from different extracts of Dysidea avara collected from 
different places (Japan, the Solomon Islands, and others), minor metabolites, analogues of avarol and 
avarone, were isolated: monoacetylavarol (42), diacetylavarol (44), 6’-hydroxy-5’-acetylavarol (43), 
4’-methylaminoavarone (58), melemeleone A (61) and melemeleone B (62). These substances were 
subjected to different biological activity assays both with regard to their cytotoxicity and their capacity 
for enzyme inhibition [54,64–66]. The cytotoxicity assays performed for diacetylalvarol (44) revealed 
levels comparable with those of avarol (38), both in tests with Artemia salina (avarol LD50 = 0.18 ppm; 
diacetylavarol, LD50 = 0.15 ppm) and potato disk assays (avarol, 64% inhibition; diacetylavarol, 55% 
inhibition). Regarding the values for enzyme inhibition, only melemeleone B (62) proved to have a 
certain activity against PTK pp60
v-sarc (dose: 20 g/mL) with an IC50 = 28 M.  
Nine alkyl(aryl)thio derivatives of avarone were synthesized by nucleophilic addition of thiols or 
thiophenol to avarone, and their cytotoxicity was compared that of aminoavarones. Most derivatives 
showed  cytotoxic  activity  against tumor cell lines (human cervical carcinoma, HeLa  cells, human 
melanoma Fem-X and human leukemia K-562), with IC50 values lower than 10 µM for some of these, Mar. Drugs 2010, 8  
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in particular those with electron-donating substituents. Most compounds showed activity against all 
three cell lines, but leukemia cells were generally the most susceptible, with IC50 values similar to 
cisplatin  for  some  methylamino  and  methoxyavarone  derivatives.  The  exceptions  were 
4’-(methylamino)avarone (58) and 3’,4’-(ethylenedithio)avarone (60), which were more active against 
melanoma cells, although overall the latter compound showed low activity. The most active compound 
was 4’-(methylamino)avarone (58), with an IC50 value of 2.4 µM against melanoma Fem-X cells, and 
no cytotoxicity against normal lymphocytes [31]. A highly efficient total synthesis of (+)-avarone,  
(+)-avarol,  (−)-neoavarone,  (−)-neoavarol  and  (+)-aureol  has  been  achieved  [67].  An  in  vitro 
cytotoxicity assay against U937 human histiocytic lymphoma cells determined the order of cytotoxic 
potency ((−)-neoavarone > (+)-avarone > (+)-aureol > (+)-avarol > (−)-neoavarol) and some aspects of 
their structure-activity relationships [67]. 
Upon  acylation,  avarol  (38)  afforded  several  compounds,  two  of  them— 
2’,5’-O-(4-bromobenzoyl)avarol  (45)  and  diacetylavarol  (44)—showed  cytotoxicity  against  Hepa 
(human  hepatoma)  and  KB  cell  lines,  respectively  [68].  The  semisynthesis  of  13  new  thioavarol 
derivatives and an in vitro evaluation of the photodamage response induced by UVB irradiation were 
described. The ability of the thioavarol derivatives prepared to inhibit NF-κB activation and TNF- 
generation in HaCaT cells, as well as their antioxidant capacity in human neutrophils, was also studied. 
The  two  monophenyl  thioavarol  derivatives  46  and  47  lacked  cytotoxicity  and  were  considered 
promising UVB photoprotective agents owing to their potent inhibition of NF-κB activation, with a 
mild antioxidant pharmacological profile [69]. A thiosalicylic derivative 64 of avarol was found to be a 
potent inhibitor of superoxide generation in human neutrophils, and it also potently inhibited PGE2 
generation in the HaCaT human keratinocyte cell line [70]. 3’-methylaminoavarone (59) had the best 
antiproliferative profile, owing to its inhibition of 3H-thymidine incorporation into HaCaT cells, with a 
potency similar to the reference compound anthralin [70]. Avinosol (65), a new merotepenoid isolated 
from the marine sponge Dysidea sp. collected in Papua New Guinea, appeared to be the first example 
of  a  naturally  occurring  meroterpenoid-nucleoside  conjugate,  and  showed  anti-invasion  activity  in 
cell-based assays [71]. 
Two sesquiterpenoids with a quinone and hydroquinone moiety, respectively, were isolated from 
the marine sponge Dysidea arenaria: arenarol (48) and arenarone (63). These compounds showed 
cytotoxic activity when assayed against P-388 leukemia cells, with ED50 = 17.5 g/mL for arenarol (48) 
and  ED50  =  1.7  g/mL  for  arenarone  (63)  [72].  Arenarol  (48)  showed  DPPH  radical  scavenging 
activity with an IC50 value of 19 M [73]. 
3. Terpenylquinones with a Labdane-Type Decalin Ring 
Two new bioactive derivatives, wiedendiol A (66) and wiedendiol B (67) (Figure 4), were isolated 
from the marine sponge Xestospongia wiedenmayeri, collected in the Bahamas [74]. The absolute 
configuration  of  these  compounds  was  determined  by  chemical  synthesis  of  wiedendiol  A  (66), 
performed  from  (+)-sclareolide  [75].  The  CETP-SPA  inhibition  assays  carried  out  with  these 
compounds revealed an IC50 = 5 M in both cases. Later, the inhibition of CETP was verified using a 
precipitation method  to  separate lipoproteins after incubation of  HDL  radiolabeled  with  LDL  and 
CETP. In this assay, wiedendiol A (66) and B (67) had an IC50 of 1.0 and 0.6 M, respectively. Mar. Drugs 2010, 8  
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Wiedendiol  B  is  a  ten-fold  stronger  inhibitor  of  cyclooxigenase-2  than  the  reference  compound 
indomethacine [76]. 
There are some compounds with a labdane-type decalin that also have a fourth ring, through an 
oxygen (most times) or carbon bridge between the decalin and the benzo(hydro)quinone ring. For 
example,  structures  with  a  fourth  five-membered  oxygen  ring,  in  this  case  spiranic,  are  the 
corallidyctals A (68), B (69), C (70) and D (71) isolated from the marine sponge Aka (Siphonodyctio) 
corallifagum [77,78]. Both corallidytal A (68) and B (69) inhibit PKC with an IC50 = 28 M, while 
assays  addressing  another  cAMP-dependent  kinase  did  not  afford  inhibition  at  concentrations  of 
300 M, indicating its selectivity. Further, the assays revealed selectivity against the  isoform of  
PKC [77]. Corallidyctals C (70) and D (71) were tested in antiproliferative assays using cultures of 
mouse fibroblasts and activity was linked to the presence of the ortho-hydroquinone moiety [78]. 
Figure 4. Wiedendiols, corallidictyals, chromazonarols and puupehenols. 
H
O
HO
O
CHO
HO
OH
H
OMe O
OH
H
H
O
OH
OH
75  puupehenol
O
OH
O
H
R
O
OH
OH
R
81   puupehedione
H
O
O
O
H
O
OSO3Na
NaO3SO
H
O
HO
OH
CHO
O
OH
H
66  wiedendiol A  (8)
67  wiedendiol B
68   corallidictyal A
69   corallidictyal B (9-epi)
70   corallidictyal C
71   corallidictyal D (9-epi)
73   ent-chromazonarol
74   8-epi-chromazonarol
72   chromazonarol
82   cyclosiphonodictyol bis-sulfate A
76 R: CN        15-cyanopuupehenol
77 R: R: MeO  15-methoxypuupehenol
78 R: =O           15-oxopuupehenol
79 R=H     puupehenone
80 R=CN  cyanopuupehenone
9
9
8
15
8
8
 
Of the compounds with a fourth six-membered oxygen ring, the first is ent-chromazonarol (73), 
isolated  from  Dysidea  pallescens  [79],  whose  structure  was  confirmed  by  chemical  synthesis 
performed  from  (−)-sclareol  [80].  Its  epimer,  8-epichromazonarol  (74),  was  isolated  from 
Smenospongia aurea [81]. Assays on cytotoxic activity were performed against P-388, A-549. HT-29 Mar. Drugs 2010, 8  
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and MEL-28 cells, and  in all cases an  IC50 = 15.9 M was obtained for ent-chromazonarol (73). 
Chromazonarol (72), isolated from the brown alga, was inactive (IC50 > 10 µg/mL) against the KB, 
Bel-7402, PC-3M, Ketr 3 and MCF-7 human tumor cell lines [82]. An enantioselective cyclisation of 
2-(polyprenyl)phenol derivatives to afford polycyclic terpenoids bearing a chroman skeleton such as 
(−)-chromazonarol by a new artificial cyclase has been described [83]. 
Two metabolites were obtained from one species of the genus Verongida: 15-cyanopuupehenol (76) 
and  15-cyanopuupehenone,  whose  structure  is  intimately  related  to  that  of  puupehenol  (75)  and 
puupehenone (80), the latter isolated from Stronylophora hartmani, collected in deep waters off the 
Bahamas  [80,84–87].  Activity  assays  performed  on  puupehenone  (79)  revealed  cytotoxic  activity 
against different neoplastic lines, with an interesting IC50 = 0.5 M against A-549 and HT-29, and 
even better inhibition values against the synthesis of DNA and RNA (0.3 and 0.4 g/mL, respectively). 
Also,  antimicrobial  assays  provided  positive  results,  especially  against  Penicilliium notatum  and 
Aspergillus  oryzae. However, in the  case of cyanopuupehenone  (78),  only its  cytotoxicity  against  
HT-29 human colon carcinoma, with an IC50 = 1–2.5 g/mL, is of interest. 
Puuppehenol  analogues  have  been  found  by  studying  different  species  of  the  genus  Hyrtios, 
collected  in  Hawaii  [84]  (from  which  15-methoxypuupehenol  (77),  the  product  of  methanol 
manipulation, was isolated) and New Caledonia (from which 15-oxopuupehenol (78) was isolated) [86]. 
15-methoxypuupehenol  showed  cytotoxic  activity (IC50  = 6  g/mL) against KB neoplastic  cells. 
Puupehenone (80) was isolated from a sponge of the genus Verongida, collected in Hawaii, together 
with other derivatives of this, among which puupehenione (81) [85] is of interest because it is one of 
the  few  orthoquinones  included  in  this  review.  Bioactivity  assays  carried  out  on  this  compound 
afforded minimum inhibitory concentration values between 1 and 2 g/mL for all the neoplastic cell 
lines analyzed. The antimicrobial tests afforded inhibition halos between 10 and 17 mm. 
Several  routes  towards  puupehenone-related  metabolites  have  been  achieved  [88–90].  
Puupehenone (79) and related compounds were selected in the course of a blind screening for new 
potential inhibitors of angiogenesis; some of them completely inhibited in vivo angiogenesis in the 
CAM  assay  at  doses  equal  or  lower  than  30  nM/egg.  They  also  inhibited  the  endothelial  cell 
production of urokinase and invasion. The simplicity of their structures and the feasibility of their 
synthesis  make  them  attractive  compounds  for  further  evaluation  in  the  treatment  of 
angiogenesis-related pathologies [91]. Puupenehone analogues from an Indo-Pacific Hyrtios sponge 
showed bioactivity in a soft-agar cytotoxicity test [92]. 
The only case of compounds with a further six-membered ring is cyclosiphonodictyol bis-sulfate A 
(82), a compound isolated from the marine sponge Siphonodictyon coralliphagum. This compound 
showed  inhibitory  activity  against  the  binding  of  [
3H]-LTB4  to  human  neutrophils,  with  
IC50 = 44.5 µM [93]. 
4. Terpenylquinones with a Halimane-Type Decalin Ring  
Within  this  group,  the  first  is  mamanuthaquinone  (83)  (Figure  5),  a  cytotoxic  metabolite  of 
Fasciospongia  sp.  collected  in  the  Fiji  islands  [94].  Activity  assays  revealed  a  certain  toxicity, 
especially against HCT-116 human colon carcinoma (IC50 = 2 g/mL). However, in vitro anti-HIV 
activity assays proved to be negative. As indicated above, nakijiquinones J (17), M (18) and P (19) at Mar. Drugs 2010, 8  
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1 mM were tested for inhibitory activity against EGFR and HER2 tyrosine kinases. Among them, 
nakijiquinones P (19) exhibited inhibitory activity against EGFR (76% inhibition) [39]. 
Other compounds with this type of skeleton are the adociasulfates 84 and 85, isolated from a sponge 
from the genus Haliclona. These two compounds were originally of interest because they were positive 
in tests studying the inhibition of the ATPase of kinesins, with an IC50 = 10 M for the former and 
15 M  for  the  latter  [95].  Smenoqualone  (86)  was  isolated  from  different  species  of  the  genus 
Smenospongia, collected from the Gulf of Aden. This compound appears to be related to a product of 
acid  rearrangement  of  5-epi-isospongiaquinone  (34),  and  its  structure  was  determined  via  its 
spectroscopic data [96]. The activity assays performed with smenoqualone revealed its inactivity as an 
antimicrobial, antifungal and cytotoxic agent, suggesting that the presence of a free hydroxyl group on 
the quinone ring is important for biological activity in this group of compounds. Strongyline A (87), a 
metabolite  isolated  from  the  marine  sponge  Strongylophora  hartmani,  showed  cytotoxic  activity 
against  P-388  leukemia  cells  (IC50  =  13  µg/mL)  and  antiviral  activity  against  Influenza  PR-8  
(IC50 = 6.5 µg/mL, IT = 9) [97]. 
Figure 5. Mamanuthaquinone, smecualone, stronglylin and adociasulfates. 
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5. Other Related Compounds 
Bolinaquinone (88) (Figure 6) is a cytotoxic sesquiterpene from the genus Dysidea, whose quinone 
moiety is located on an unusual carbon of the decalin [98]. This compound showed cytotoxic activity 
against HCT-116 human colon carcinoma (IC50 = 1.9 µg/mL). The cytotoxicity studies carried out 
suggest that this compound acts by interfering with or damaging DNA. Dehydroxybolinaquinone (89), 
isolated from the Hainan sponge Dysidea villosa, showed moderate PTP1B inhibitory activity and 
cytotoxicity, with IC50 values of 39.5 and 19.5 mM, respectively [99]. The sequiterpene aminoquinone 
dysidine (90) [100], isolated from Dysidea sp., had the strongest hPTP1B inhibitory activity, with an 
IC50  value  of  6.7  mM  [99].  Methoxyhalenaquinone  (91)  from  Xestopolospongia  carbonara  is  a 
tyrosine kinase inhibitor [101]. Mar. Drugs 2010, 8  
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Figure 6. Bolinaquinones, renierins, paniceins, popolohuanones and other compounds. 
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An important number of metabolites with very diverse structures have been isolated from the genus 
Reniera, such as carotenes, alkaloids, diacetylenes and terpenequinones. In particular, four metabolites 
with a sesquiterpene structure were isolated from the species Reniera fulva, with the novelty that they Mar. Drugs 2010, 8  
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did not have the B ring of the decalin, the most significant compound being fulvanin-2 (92) [102]. 
Additionally, apart from fulvanins, the fractionation of the acetone extract of Reniera mucosa afforded 
another five compounds with analogous structures: paniceins A2 (93) and F1 (94), renierins A (95) and 
B (96), and p-hydroquinone [103]. All the compounds obtained from Reniera mucosa were assayed 
against the P-388, A-549, HT-29 and MEL-28 cell lines with a view to determining their in vitro 
cytotoxicity. Among them, of interest were panicein A2 (93) (ED50 = 5 µg/mL against all the lines 
assayed) and panicein F1 (94) (ED50 = 5 µg/mL against all cell lines except HT-29), the latter showing 
medium potency in additional DHFR inhibition tests (ED50 = 3 µg/mL). 
New terpenylquinones were isolated from different species of the genus Dysidea; their structures 
are formed by two subunits, called popolohuanones. Thus, from a specimen of that genus, collected in 
Papua New Guinea, popolohuanones A (97) and B (98) were isolated [104], whereas popolohuanones 
C  (99)  and  D  (100)  were  isolated  from  Dysidea  avara,  collected  in  the  Solomon  Islands  [64]. 
Cytotoxicity assays for popolohuanone A (97), performed against KB cells at concentrations of 10, 5 
and 1 µg/mL, proved to be negative. Identical results were obtained in antimycotic activity assays 
against Candida albicans. Other related compounds were isolated from species of the genus Hyrtios 
(New Caledonia), such as dipuupehenone (101) and bispuupehenone (102), the latter also found in the 
species  Hyrtios  eubamma  (Tahiti).  Bioactivity  assays  of  these  compounds  unveiled  the  cytotoxic 
activity of dipuupehedione (101) against KB cells (ED50 = 3 µg/mL). Popolohuanone E (103), a potent 
topoisomerase II inhibitor with selective cytotoxicity against the A549 non-small cell human lung 
cancer cell line, was isolated from Dysidea sp. Pohnpei sponges [105], and the biomimetic route to this 
family of heterocyclic ring systems has been proposed [106]. Popolohuanone A (96) and the new 
dimeric  popolohuanone  F  (104)  showed  DPPH  radical  scavenging  activity,  with  an  IC50  value  of 
35 µM [73]. 
A biosynthetic pathway leading to several sesquiterpene quinones is suggested [107]. 
6. SAR Studies and Mechanism of Action 
Sesquiterpenoid quinones from marine sponges and their semisynthetic derivatives were compared 
for cytotoxicity on developing eggs of the sea urchin Strongylocentrotus nudus and Ehrlich carcinoma 
cells, and for hemolytic activities on mouse red blood cells. Structure-cytotoxicity studies of several 
marine sesquiterpenoid quinones and their semisynthetic derivativess on developing eggs of the sea 
urchin  Strongylocentrotus  nudus  and  Ehrlich  carcinoma  cells  revealed  that  the  activities  of  these 
compounds, with a hydroxyl group at C-20, were higher than their methoxyl and amino groups at this 
position. Sesquiterpenoid quinones containing a dihydropyran ring had lower activity than non-cyclic 
compounds. The structure of the terpenoid moieties of the compounds had no significant influence on 
biological activity. There was a direct correlation between the cytotoxic and hemolytic activities, and 
the  mechanisms  of  action  employed  by  these  compounds  against  cell  membranes  have  been 
discussed [108].  Other  results  from  SAR  studies  appear  in  the  description  of  the  different  types 
of compound. 
Regarding the mechanism of action of terpenylquinones, the accumulated data about the biological 
activity  of  quinone  moieties  suggest  redox  processes  and/or  Michael-type  addition-elimination 
reactions [31]. Their cytotoxicity has been explained in terms of their ability to undergo redox cycling Mar. Drugs 2010, 8  
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and  the  generation  of  reactive  oxygen  species,  which  would  damage  tumor  cells  [109–111]. 
NADH/NADH dehydrogenase reduction of the several terpenylnaphthoquinones increases the rate of 
oxygen consumption, such rates being higher for quinones with more positive redox potentials. In this 
process, reactive oxygen species are formed in small amounts, which also correlate with the quinone 
redox potential. Semiquinone derivatives of these quinones are generated under anaerobic conditions 
and  in  the  presence  of  NADH/NADH  dehydrogenase.  Since  this  enzymatic  system  is  found  in 
mitochondria, a possible pathway in the cytotoxic activity of these terpenylnaphthoquinones could be 
interference with or the inhibition of mitochondrial respiration, as reported for other naphthoquinone 
derivatives, in addition to free  radical degradation [29,30]. The results obtained with avarone and 
avarol supported the mechanism of antitumor action via the reactive oxygen radicals [112,113], but 
there were also indications of the relevance of arylation of biomolecules, such as proteins [31,114,115]. 
7. Summary  
The  compounds  that  appear  in  this  review  are  meroterpenes,  compounds  of  mixed  biogenesis 
isolated  from  marine  sources  and  mainly  from  the  following  genera:  Dactylospongia,  Dysidea, 
Euryspongia,  Fasciospongia,  Fenestraspongia,  Haliclona,  Polifibospongia,  Siphonodictyon, 
Smenospongia, Stelospongia, Strongylophora, Reniera and Xestospongia. The cytotoxic properties of 
sesquiterpenequinones  or  quinols  produced  by  these  genera  make  them  viable  candidates  for 
continuing  the  search  for  analogues  with  enhanced  cytotoxicity,  improved  selectivity  and  able  to 
eliminate  adverse  effects  with  a  view  to  finding  new  drugs  of  marine  origin  [3,5,19,24–26]. 
Outstanding  among  the  compounds  investigated is 4’-(methylamino)avarone (58), with an  IC50 of 
2 µM against melanoma Fem-X cells, and non-cytotoxic to normal lymphocytes [31]. 
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